Puma Biotechnology (PBYI) Income from Continuing Operations (2010 - 2026)
Puma Biotechnology (PBYI) posted Income from Continuing Operations of 3753000.0 for Q1 2026, down 122.26% on a QoQ basis from 16862000.0 in Q4 2025, and down 226.19% year-over-year from 2974000.0 in Q1 2025.
Puma Biotechnology (PBYI) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Puma Biotechnology's Income from Continuing Operations history runs 17 years deep, the most recent figure standing at 3753000.0 for Q1 2026.
- Quarterly Income from Continuing Operations fell 226.19% year-over-year to 3753000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 27808000.0 (up 265.22% YoY) and the FY2025 annual result came in at 34535000.0, up 19834.29% from the prior year.
- Income from Continuing Operations was 3753000.0 for Q1 2026 at Puma Biotechnology, down from 16862000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 20317000.0 in Q3 2024 and bottomed at 11148000.0 in Q4 2024.
- A 5-year average of 3107823.53 and a median of 2126000.0 in 2023 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2023 — Income from Continuing Operations surged 1710.0% — and 2024, when it sank 443.68%.
- Puma Biotechnology's Income from Continuing Operations stood at 5151000.0 in 2022, then soared by 341.62% to 12446000.0 in 2023, then slumped by 189.57% to 11148000.0 in 2024, then soared by 251.26% to 16862000.0 in 2025, then slumped by 122.26% to 3753000.0 in 2026.
- Business Quant data shows PBYI's Income from Continuing Operations at 3753000.0 in Q1 2026, 16862000.0 in Q4 2025, and 8844000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Puma Biotechnology | 407.27 Mn | 368.99 Mn | 34.39 Mn | -3.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.75 Mn |
| Dec 31, 2025 | 16.86 Mn |
| Sep 30, 2025 | 8.84 Mn |
| Jun 30, 2025 | 5.86 Mn |
| Mar 31, 2025 | 2.97 Mn |
| Dec 31, 2024 | -11.15 Mn |
| Sep 30, 2024 | 20.32 Mn |
| Jun 30, 2024 | -4.53 Mn |
| Mar 31, 2024 | -4.82 Mn |
| Dec 31, 2023 | 12.45 Mn |
| Sep 30, 2023 | 5.80 Mn |
| Jun 30, 2023 | 2.13 Mn |
| Mar 31, 2023 | 1.40 Mn |
| Dec 31, 2022 | -5.15 Mn |
| Sep 30, 2022 | -360,000.00 |
| Jun 30, 2022 | 9.37 Mn |
| Mar 31, 2022 | -3.40 Mn |
| Dec 31, 2021 | 4.22 Mn |
| Sep 30, 2021 | -44.67 Mn |
| Jun 30, 2021 | -5.11 Mn |